Objectives. Rituximab has been shown to induce remission of ANCA-associated vasculitides (AAVs). Our study was undertaken to describe AAV clinical responses to rituximab used for remission-induction and/or maintenance therapy, assess rituximab's safety profile and evaluate French clinical practices.
Introduction
Rituximab is a chimeric murine human monoclonal IgG1 antibody directed against CD20 lymphocytes. It was used to treat ANCA-associated vasculitides (AAVs) for the first time in 2001 [1] . Since then, results obtained with rituximab in a few retrospective series of patients refractory to corticosteroids and immunosuppressants or relapsing under treatment have been reported [26] . Those findings were promising since, according to Jones et al.
[2], 75% of their patients achieved complete remission and Holle et al. [3] found that 61.3% of patients with refractory granulomatosis with polyangiitis (GPA) improved. However, rituximab did not seem to be as good at curing granulomatous manifestations of AAV [3, 7] , especially orbital masses. The results of two prospective, randomized controlled studies [8, 9] showed that rituximab was as effective as CYC at inducing AAV remission. In April 2011 the US Food and Drug Administration (FDA) approved rituximab combined with corticosteroids for the treatment of adults with GPA or microscopic polyangiitis (MPA). Unlike other autoimmune disorders in which severe infections, e.g. progressive multifocal leucoencephalopathy, have been observed [10] , no major safety issues were raised for AAV patients treated with rituximab, even though they were sometimes immunocompromised by previous immunosuppressive therapies.
The objectives of our study were to describe AAV clinical responses to rituximab prescribed for remissioninduction and/or maintenance therapy, to evaluate the safety profile of rituximab and to describe French clinical practice (dose and administration schedule, duration and associated monitoring) concerning rituximab.
Patients and methods

Study design
This retrospective study was conducted in France under the auspices of the French Vasculitis Study Group (FVSG).
Selection of patients
To be included, patients had to have AAV satisfying the definitions of the Chapel Hill nomenclature [11] . Histological confirmation of the diagnosis and/or ANCA detection by immunofluorescence and specificity determination by ELISA were also required for eligibility. All patients had to have received at least one rituximab infusion between January 2002 and January 2011 and had to have been followed for a minimum of 12 months (except for those who died before 12 months). Rituximab could be used as first-line treatment, as second-line therapy for a relapse or refractory disease or as maintenance therapy. Patients included in the ongoing MAINRITSAN prospective trial (NCT00748644), comparing rituximab with AZA for maintenance, were not eligible. This study was conducted in compliance with the good clinical practices protocol and the Declaration of Helsinki principles. In accordance with French law, formal approval from an ethics committee was not required for this type of study.
Data extraction
Each patient's data from his/her medical file were collected onto a standardized form (by P.C.) at the treatment site. The following information was recorded: before the first rituximab infusion, demographic characteristics, type of vasculitis, ANCA results for the cANCA or pANCA labelling pattern assessed by indirect immunofluorescence, ANCA specificity for MPO or PR3 (ELISA) and organ involvement at the time of AAV diagnosis; and when rituximab was prescribed, AAV duration, number of relapses, treatments received before the first rituximab infusion or combined with rituximab, cumulative CYC dose, other drugs/agents used [AZA, MTX, MMF, infliximab (IFX), adalimumab, IVIG] and their duration, cumulative corticosteroid dose 2 weeks before rituximab infusion, BVAS 2003 [12, 13] , Disease Extent Index (DEI) [14] , Vasculitis Damage Index (VDI) [15] and creatinine clearance calculated with the Modification of Diet in Renal Disease formula [16] . The outcomes of rituximab administration were evaluated, based on the same list of items. European League Against Rheumatism (EULAR) definitions of remission and relapses were applied [17] . We also examined why rituximab was prescribed: high cumulative CYC dose, multiple relapses, history of cancer, patient's preference, young woman wanting to preserve fertility and other(s). Administration modalities were recorded (dose, number of infusions, combination with other immunosuppressants, maintenance treatment chosen when rituximab had been used for induction), whether patients had received pneumococcal vaccination and if CD19 and weighted immunoglobulin (IgG, IgA, IgM) levels were determined during follow-up.
At 6 and 12 months, all patients were systematically evaluated with BVAS, DEI and VDI, and their corticosteroid doses recorded. During follow-up, relapses were described, CD19 + lymphocyte counts determined and time since first and last rituximab infusion noted. We also recorded serious adverse events (SAEs) possibly or probably imputable to rituximab (infectious complications, neutropenia, other). When an infection occurred, CD19 and immunoglobulin dosages were obtained.
Statistical analysis
The descriptive analyses included mean (S.D.) or median [interquartile range (IQR)] depending on the distribution of continuous variables and number (percentage) for qualitative variables. Relapse-free survival was estimated using the KaplanMeier method with log-rank tests for significance. For all analyses, the a risk was set at 5%. All analyses were computed with the R v2.4.2. software package (http://www.R-project.org). Patient characteristics at the time of the first rituximab infusion Seventy-three (91%) patients received their first rituximab cycle for remission induction and seven (9%) for maintenance (Table 1) . Seventy-nine (99%) patients received one or more immunosuppressants before rituximab. Only one patient was prescribed rituximab as first-line therapy: she refused CYC because of its gonadal toxicity. The other reasons for using rituximab are given in Table 2 . Among the 73 (91%) patients with active disease, 32 (44%) had a granulomatous form (e.g. orbital masses, pachymeningitis, severe ENT granuloma, pulmonary nodules). Median creatinine clearance was 77 (IQR 4990) ml/min/1.73 m 2 ;
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three patients required haemodialysis. Organ involvement at the time of the first rituximab infusion is reported in Table 2 .
Modalities of rituximab administration
Four different protocols were used to administer rituximab for remission induction (Table 3) , with the two most frequently chosen regimens being an infusion per week of 375 mg/m 2 for 4 weeks (54 patients) or a 1 g infusion every 2 weeks for a month (16 patients). Twenty (25%) patients took concomitant immunosuppressants. Seventy patients received maintenance therapy according to several different regimens (Table 3) . For maintenance therapy, 64 patients received rituximab, either alone or combined with another immunosuppressant. Before the first rituximab infusion, only 15 (19%) patients had been vaccinated against pneumococcal infection. CD19 lymphocyte counts were determined for 54 (68%) patients and immunoglobulin dosages were measured in 45 (56%) patients. Sixty-five patients received one rituximab cycle as remission-induction therapy and eight patients received two cycles. As maintenance therapies, 10, 18, 13, 3, 3, 2, 1 and 1 patients received 1, 2, 3, 4, 5, 6, 8 and 10 rituximab cycles, respectively.
Rituximab efficacy
At 6 months, 51/77 (66%) and 19/77 (25%) patients obtained complete or partial remission, respectively, and 7 (9%) patients still had active disease (Table 4) . Responses did not seem to differ according to organ involvement (Table 2 ). For patients with granulomatous manifestations, none of the five with orbital masses achieved complete remission, but 77% of patients with pulmonary nodules and 55% with ENT involvement and upper airway stenoses obtained complete remission.
Median follow-up was 18 months (IQR 1237). Respective 1-, 2-and 3-year relapse-free survival rates after the first rituximab infusion were 80%, 63% and 52%, respectively. No difference between relapse-free survival rates was observed, regardless of whether patients took rituximab alone or combined another immunosuppressant (P = 0.96). Eighteen (23%) patients relapsed after a median time of 11.8 (IQR 9.313) months after the last rituximab infusion. Only two patients relapsed before 6 months after the last rituximab infusion. Organ involvement at the time of relapse was lung and lower airways in 10 (56%) patients, ENT manifestations in 6 (33%), eye involvement in 4 (22%), skin in 2 (11%), constitutional symptoms in 2 (11%) and kidney, neuropsychiatric disorder and heart in 1 each (6%). Among patients in complete or partial remission at 6 months, 8 (44%) of the 19 patients who had not received rituximab as maintenance therapy relapsed or died vs 10 of the 51 (20%) patients given one or more additional rituximab-booster doses (P = 0.002) (Fig. 1) .
At the time of relapse, CD19 was determined for only eight patients and their median CD19 + cell count/mm 3 was 4 (IQR 015, range 0666). ANCA was sought for 17 relapsing patients: among them, ANCA was positive for 11 (65%) patients [PR3-ANCA for 9 (82%), MPO-ANCA for 1 (9%) and without specificity for 1 (9%)].
Safety
In the whole population, 22 SAEs were documented, predominantly infectious complications [n = 12 (15%)], particularly pulmonary infections (n = 8) (Table 5 ). Other infections (one each) were septic shock, pyelonephritis, erysipelas, pneumococcal meningitis and febrile neutropenia. Outcome was severe for six (8%) patients: four (5%) died, one was hospitalized in an intensive care unit and one underwent pulmonary lobectomy for aspergillosis. Three of the four deaths were directly attributed to infection, while the fourth (patient 2; Table 5 ) succumbed to uncontrolled vasculitis and immunosuppressant-related sepsis. The other SAEs were three episodes of macular oedema and one each of grade IV neutropenia, acute psychosis, acute neuropathy, pulmonary oedema, metastatic sarcoma, cutaneous carcinoma and thrombophlebitis. No patient experienced a severe reaction during infusions.
Discussion
Since Stone et al. [8] , Jones et al. [9] and several patient series and case reports demonstrated that rituximab Values are n (%). AAV: ANCA-associated vasculitides.
www.rheumatology.oxfordjournals.org induces AAV remission as effectively as CYC, this agent has been prescribed more frequently as first-line therapy to obtain remission and for relapses or non-responders to conventional immunosuppressants. Some physicians also prescribe rituximab to maintain remission, even though such use has not been supported by prospective trials. The purpose of this retrospective multicentre study was to analyse how rituximab is prescribed, for whom and how it is administered. We also examined the responses to therapy in real-life situations and described patient outcomes, including SAEs. Rituximab has been accorded a central role in the treatment of AAV relapses (61 included patients had one or more relapses) and, after failure of a first-line imunosuppressant, it is now preferred to second-line immunosuppressants. Nonetheless, Stone et al. [8] demonstrated that the risks of rituximab or CYC side effects, including infections, at 6 months are similar. Jones et al. [9] also showed that the infectious risk is higher when immunosuppressants are combined with rituximab. In our study, 11 of the 12 patients experiencing a serious infection had received high doses or prolonged other immunosuppressant therapy before their first rituximab and three had received a combination of rituximab and other immunosuppressants. Immunoglobulin monitoring was performed for 50% of patients and 33% received anti-pneumococcal vaccination (Table 5) . Notably, two of the four patients who died had been vaccinated. 
FIG. 1
Relapse-free survival rates of patients in remission at 6 months according to whether or not they had received one or more rituximab boosters as maintenance therapy.
TABLE 5
Description and outcomes of the 12 patients with infectious serious adverse events after rituximab Relapse-free survival rates during the first 3 years of follow-up were good. Rituximab effectively achieved AAV remission: 64% of the 99 RAVE trial patients (8) and 75% of the 65 patients in Jones et al.'s study [2] obtained complete remission.
Although response rates of GPA with predominant granulomatous manifestations were lower, rituximab is considered a therapeutic option because partial remission or stabilization could be achieved [3] . In our study including many refractory and relapsing AAV patients, the complete remission rate was 60%, which also seems promising in light of patient characteristics. Patients with orbital masses had poorer outcomes with rituximab, but other granulomatous manifestations responded well, contrary to a previous report [3] . This latter response could be explained by our population, which included many relapsing and few refractory AAV patients.
Many of our patients received rituximab booster doses as maintenance therapy, administered according to heterogeneous protocols. Rituximab in this indication was superior to other maintenance therapies, with results close to those previously published [18] . Optimal rituximab administration has not yet been determined: in the French experience, low rituximab doses have generally been prescribed-an infusion of 375 mg/m 2 or 500 mg every 6 months in this study, 500 mg every 6 months in an ongoing randomized-controlled trial vs AZA (MAINRITSAN). Twelve (15%) severe infections, eight involving the lungs and four leading to death, were documented. These observations are close to those previously reported, i.e. 728.9% infection rates [3, 4, 8, 9, 18] , but the latter infections were less severe and were considered acceptable in terms of toxicity. Infections occurring in our study were particularly severe. For example, a 40-year-old woman with no history of infection, correctly vaccinated against Streptococcus pneumoniae and with normal immunoglobulin dosages died within 48 h after developing pneumococcal meningitis 3 weeks after the first rituximab infusion (Table 5 , patient 1). We also noted two cases of aspergillosis, one of which led to pulmonary lobectomy (Table 5 , patient 9). Neither pneumocystosis nor progressive multifocal leucoencephalopathy was observed. Even though we cannot reach any conclusion as to the causality of rituximab in the occurrence of severe infections, since our patients also received other immunosuppressants and corticosteroids, close monitoring is needed when rituximab is prescribed and the combination of rituximab with other immunosuppressive therapies should be avoided.
The results of this multicentre study conducted in France showed an absence of harmonization of practice, as the modalities of rituximab prescription and use were highly heterogeneous: four different infusion protocols when rituximab was given for remission induction and more than five schedules for maintenance therapy, combined or not with other immunosuppressants. This absence of homogeneous therapy could be explained by the lack of available recommendations, as Stone et al. [8] had not yet published their findings when the patients received rituximab. What is even more worrying is that only 19% of our patients had been vaccinated against pneumococcal infections before the first rituximab infusion and immunoglobulin dosages were available for only 56%, while recommendations for rituximab use, particularly for RA patients, are available and regularly updated [19] .
Our study has several limitations. It is a retrospective multicentre study on patients who had received rituximab between 2002 and 2010. Their management and monitoring were highly diverse, probably resulting from the long recruitment period. Moreover, we did not have sufficient data to analyse the value of CD19 and ANCA as predictors of relapse and the immunoglobulin dosage as a predictor of infection.
To conclude, rituximab effectively induced AAV remission and seems to achieve superior remission maintenance compared with standard therapy. Nevertheless, prudence is warranted in light of the severe bacterial and fungal infections observed after its administration. The optimal rituximab dose for maintenance therapy has not yet been determined and clinicians should follow available recommendations (vaccinations, monitoring) [20] .
Rheumatology key messages
. Rituximab is efficient in inducing and maintaining remission in ANCA-associated vasculitides. . Patients receiving rituximab must be closely monitored because of the risk of severe infectious complications.
